Fintel reports that on March 17, 2025, HC Wainwright & Co. downgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) from ...

H.C. Wainwright says that competitor data demonstrate impressive ORR in endometrial cancer, opening a potential opportunity for NetCure’s ...

Fintel reports that on March 17, 2025, HC Wainwright & Co. initiated coverage of Actuate Therapeutics (NasdaqGM:ACTU) with a ...

In a report released today, Kevin Dede from H.C. Wainwright maintained a Hold rating on Biotricity (BTCY – Research Report). The company’s ...

HC Wainwright reaffirmed their buy rating on shares of Emeren Group (NYSE:SOL – Free Report) in a report released on ...

HC Wainwright reissued their buy rating on shares of Atyr PHARMA (NASDAQ:ATYR – Free Report) in a research note published on Friday morning,Benzinga reports. They currently have a $35.00 price ...

H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.

The establishment of a Strategic Bitcoin Reserve (SBR) in the U.S. is a "monumental endorsement" of the world's largest ...

Ten companies across mixed sectors also mirrored a broader market optimism, booking modest gains during the end of the ...

H.C. Wainwright analyst Amit Dayal initiated coverage on Surf Air Mobility Inc. (NYSE:SRFM) with a Buy rating and price forecast of $12. The analyst writes that the company is positioned for a ...